Latest IMPH Community News

Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of “convalescent plasma” as a treatment for COVID-19. The randomized, controlled trial will test whether infusions of plasma, the liquid part of blood collected from COVID-19 survivors, can help other hospitalized patients with COVID-19. The plasma contains antibodies against SARS-CoV-2, the virus that causes COVID-19.

The Critical Illness, Brain Dysfunction and Survivorship Center at Vanderbilt University Medical Center is following patients who have been hospitalized for COVID-19 over time to see if they develop long-term cognitive impairment, depression or post-traumatic stress disorder (PTSD). These disabling features suffered by millions of ICU survivors are called Post-Intensive Care Syndrome (PICS).

Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. “We urgently need to find effective treatments for COVID-19, especially for patients who develop severe lung injury from the virus,” said co-principal investigator Wesley Self, MD, an emergency medicine physician at Vanderbilt University Medical Center.

Vanderbilt University Medical Center investigators are leading a new study that examines the transmission of SARS-CoV-2, the virus that causes COVID-19, within households in Nashville. The study funded by the Centers for Disease Control and Prevention (CDC) aims to understand how fast the infections spread within households and the factors that may be associated with that transmission. This is one of few longitudinal studies in the country that will examine coronavirus infections among close contacts.

The Vanderbilt Institute for Clinical and Translational Research (VICTR) and RTI International, a non-profit clinical research organization based in North Carolina, have been named Administrative Coordinating Center (ACC) of a national effort to st

Early data assessing the primary language of those who received COVID-19 tests at Vanderbilt University Medical Center, and tested positive, illustrates the disproportionate impact the pandemic is having on racial or ethnic communities. Of the first 18,491 patients tested for the novel coronavirus, 1,063 speak 37 languages other than English, according to analysis of electronic health records by VUMC’s Office of Health Equity. Although this group represents 5.7% of those tested, they are 19.4% of those positive and the highest number reside in two adjacent Nashville ZIP codes.

Researchers at Vanderbilt University Medical Center are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families. The study, named the HEROS (Human Epidemiology and Response to SARS-CoV-2) study and funded by the National Institute of Allergy and Infectious Diseases (NIAID), aims to gain insight into how many children ages 1 to 21 have been infected, the percentage of those infected who develop symptoms of COVID-19 and any differences in immune responses to the virus between children and adults within the same household.

Out of the electronic health records (EHRs) of patients seen at Vanderbilt University Medical Center, a team in the Department of Biomedical Informatics is creating a COVID-19 patient registry as a platform for research.

Vanderbilt University Medical Center is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.